权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies on efficacy evaluation and prediction of side effect of cancer chemotherapy using positron CT.

正电子CT肿瘤化疗疗效评价及毒副作用预测研究

基本信息

批准号：
61570299
负责人：
TAKAHASHI Hiromu
金额：
$ 1.54万
依托单位：
TOHOKU UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1986
资助国家：
日本
起止时间：
1986 至 1988
项目状态：
已结题

项目摘要

Glucose demand is one of the physiological characteristics of tumor cells, the myocardium and the brain. ^<18>FDG(2-deoxy-2-(^<18>F)fluoro-D-glucose), positron-labelled glucose analog is taken in tumor cells and the myocardium like glucose but trapped in the glucolysis pathway. On the basis of this property ^<18>FDG was used as tracer for detecting cancer with positron emission tomography(PET).We report the results obtained by comparing the change of the image, which was clinically constructed using PET with ^<18>FDG during chemotherapy, to the current efficacy evaluation.A total of 10 advanced cancer patients were examined. Following the injection of ^<18>FDG, serial emission scans by ECAT II were performed on the primary or metastatic tumor as determined by X-CT. We attempted quantification of ^<18>FDG concentration in tumors as follows : DAR(Differential Absorption Ratio)=(PET count x calibration factor)/(injected dose/body weight). In addition, their changes caused by the treatment … More were calculated and denoted as DAR-ratio(DAR at examination/ DAR at previous examination). The categories of efficacy・obtained by the evaluation method of the Japan Society for Cancer Therapy and changes of the scanning images as well as DAR-ratio were compared. In 10 cases, there was a significant relationship between the efficacy evaluation by current method and that by the change of ^<18>FDG-PET imaging. With regard to the change of quantitative expression of ^<18>FDG uptake in the tumor, expressed as DAR-ratio, nonresponder had the DAR-ratio of over 1.0, while that of responder was under 0.7. No inconsistency was found between these values and the categories of efficacy evaluation by current method.This method not only expressed morphological change of tumors but can quantify metabolic change in tumor tissues by chemotherapy. Analytic studies on tumor image by ^<18>FDG-PET seem to be promising for the evaluation of efficacy of cancer chemotherapy.It was expermentally observed with rats that the ^<18>FDG uptake into the heart decreased 3 days after the adriamycin of THP-Adriamycin administration. The similar result was seen with other kinds of anthracyclines : aclacynomycin or KRN 8602(under development). Clinically, the DAR of ^<18>FDG-PET-Cardial Image was relatively low in the cases administered with anticancer drugs compared to those without anticancer drugs. We are convinced that the results will contribute to the future study to detect the mechanism that causes cardiotoxicity of anticancer drugs. Less

葡萄糖需求是肿瘤细胞、心肌和大脑的生理特征之一。 18 FDG(2-脱氧-2-(18 F)氟-D-葡萄糖)，正电子标记的葡萄糖类似物，像葡萄糖一样被摄入肿瘤细胞和心肌中，但被困在糖酵解途径中。基于这一特性，^ 18 FDG被用作正电子发射断层扫描（PET）检测癌症的示踪剂。我们通过比较临床上使用PET与^ 18 FDG在化疗期间构建的图像的变化与目前的疗效评估所获得的结果进行比较。总共对10名晚期癌症患者进行了检查。注射18 FDG后，通过ECAT II对原发性或转移性肿瘤进行连续发射扫描，如通过X-CT确定的。我们尝试如下定量肿瘤中的^ 18 FDG浓度：DAR(差异吸收比)＝(PET计数x校准因子)/(注射剂量/体重)。此外，计算治疗引起的变化并表示为 DAR 比率（检查时的 DAR/上次检查时的 DAR）。比较根据日本癌症治疗学会的评价方法获得的疗效类别和扫描图像以及DAR比的变化。在10例中，当前方法的疗效评估与^ 18 FDG-PET成像变化的疗效评估之间存在显着相关性。关于肿瘤中18 FDG摄取的定量表达的变化，以DAR比率表示，无应答者的DAR比率超过1.0，而应答者的DAR比率低于0.7。这些值与现有方法评价疗效的类别没有发现不一致。该方法不仅能够表达肿瘤的形态变化，而且可以量化化疗后肿瘤组织的代谢变化。通过^ 18 FDG-PET对肿瘤图像的分析研究似乎有望用于评估癌症化疗的功效。用大鼠实验观察到，在给予THP-阿霉素的阿霉素后3天，心脏的^ 18 FDG摄取减少。其他种类的蒽环类药物：阿卡霉素或 KRN 8602（正在开发中）也出现了类似的结果。临床上，与未施用抗癌药物的病例相比，施用抗癌药物的病例中18 FDG-PET-心脏图像的DAR相对较低。我们相信，这些结果将有助于未来研究发现抗癌药物心脏毒性的机制。较少的